RESUMO
A survey of experimental and clinical data on the spectrum of immunotropic effects of H1-histamine blockers is presented. The mechanisms and role of the blockade of H1-histamine receptors in the immunotropic effect of the drugs are discussed.
Assuntos
Adjuvantes Imunológicos/farmacologia , Antagonistas dos Receptores Histamínicos H1/farmacologia , Adjuvantes Imunológicos/uso terapêutico , Animais , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Liberação de Histamina/efeitos dos fármacos , Humanos , Imunidade Celular/efeitos dos fármacos , Receptores Histamínicos H1/efeitos dos fármacos , Receptores Histamínicos H2/efeitos dos fármacosAssuntos
Acetilmuramil-Alanil-Isoglutamina/farmacologia , Adjuvantes Imunológicos/farmacologia , Hidrocortisona/sangue , Lipopolissacarídeos/farmacologia , Fígado/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Animais , Inibidores das Enzimas do Citocromo P-450 , Feminino , Fígado/enzimologia , Fígado/metabolismo , Ativação de Macrófagos , Macrófagos/imunologia , Masculino , CamundongosRESUMO
The experiments carried out on mongrel male mice showed that bacterial lipopolysaccharide Prodigiozan inhibit the activity of P-450-dependent monooxygenases of the liver, thus changing the activity of antidepressants--amitriptyline and imipraminum. The data on biological activity were tested in "tail suspension" test. Prodigiozan exhibited no central effect. Changes in biotransformation processes after single administration of both drugs resulted in the delay and prolongation of the effect. Prodigiozan prevents the induction of microsomal enzymes caused by antidepressants. Amitriptyline do not affect the immunostimulating action of prodigiozan, whereas imipraminum inhibited prodigiozan activity.
Assuntos
Adjuvantes Imunológicos/farmacologia , Amitriptilina/farmacologia , Antidepressivos Tricíclicos/farmacologia , Imipramina/farmacologia , Prodigiozan/farmacologia , Adjuvantes Imunológicos/uso terapêutico , Amitriptilina/toxicidade , Animais , Antidepressivos Tricíclicos/toxicidade , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Interações Medicamentosas , Imipramina/toxicidade , Masculino , Camundongos , Prodigiozan/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/mortalidade , Sono/efeitos dos fármacos , Fatores de TempoRESUMO
The effect of different immunostimulants (prodigiosan, levamisole, T-activin, sodium diethyl dithiocarbamate, sodium nucleinate, lithium chloride, muramil dipeptide, B-activin) and mixed hepatic function oxidase inhibitors (cimetidine, chloramphenicol) or inducers (phenobarbital, flumecinol, rifampicin) on immune reactivity (macrophage function, humoral and cellular responses) and hepatic microsomal function (hexobarbital sleeping-time) was studied in non-inbred and BALB/c male mice. There was a high correlation between the ability of immunostimulants to depress hexobarbital metabolism and their ability to enhance macrophage activity (carbon clearance test), but not humoral and cellular immunity. No reciprocal changes occurred in immune reactivity after positive or negative pharmacological modulation of hepatic drug metabolizing enzyme activity.
